FDA Orange Book · active-ingredient family
Ciprofloxacin hydrochloride; hydrocortisone
Ciprofloxacin hydrochloride; hydrocortisone is approved as 1 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:CIPRO HC · NDA 020805
1
Brand (NDA)
1
Generics (ANDA)
0
Listed patents
1
Exclusivity periods
Brand (NDA) products · suspension/drops
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CIPRO HCRLD | SANDOZ | NDA 020805 | AB | Feb 10, 1998 |
Generic (ANDA) products (1)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE | COSETTE PHARMS NC | ANDA 218273 | AB | Nov 10, 2025 |
Marketing exclusivity (1)
- CGTFDA marketing exclusivity
Jun 02, 2026
17 d ago
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Ciprofloxacin hydrochloride; hydrocortisone — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

